Schrodinger
SDGR
27.29
-1.61
-5.57%
Schrodinger
US · SDGR
#2667 by market cap
Listed 2020
27.29
-1.61
-5.57%
Live - 5344 symbols - heartbeat 79s ago
· 2026-10-08 06:53
Pre-market
26.80
-1.80%
After-hours
27.20
-0.33%
Overnight
27.29
0.00%
- Market cap
- 2.04B
- P/E (TTM)i
- -37.38
- P/Bi
- 6.21
- EPSi
- -1.41
- Div yieldi
- 0.00%
- 52W posi
- 72%
Reader sentiment
Are you bullish or bearish on SDGR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 6.3 percentage points.
Institutional ownership
- Held by institutions
- 96.70% -6.35pp
- Institutions
- 281 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund53.31%
Foundation21.58%
Hedge Fund16.02%
Public Company2.54%
Individual/Insider2.53%
Private Company1.99%
Government Pension Fund0.63%
Insurance Company0.43%
Family Office/Trust0.14%
Other0.82%
Top holders as of 2026-06-30
Bill & Melinda Gates Foundation Asset Trust
21.58% · 16.15M sh
BlackRock
14.07% · 10.52M sh
Rubric Capital Management LP
8.56% · 6.40M sh
Vanguard Portfolio Management, LLC
5.06% · 3.79M sh
UBS Asset Management
4.26% · 3.19M sh
Vanguard Capital Management, LLC
4.15% · 3.10M sh
Amova Asset Management
3.62% · 2.71M sh
State Street Global Advisors
3.07% · 2.30M sh
ARK Investment Management LLC
2.88% · 2.15M sh
AQR Capital Management
2.59% · 1.94M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Bill & Melinda Gates Foundation Asset Trust | -- | 21.58% |
| Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | 1.88% |
| Ramy Farid | Chief Executive Officer | 0.36% |
| Kenneth Lorton | Executive Vice President | 0.05% |
| Arun Oberoi | Independent Director | 0.02% |
| Rosana Kapeller-Libermann | Independent Director | 0.02% |
| Gary Sender | Independent Director | 0.02% |
| Gary Ginsberg | Independent Director | 0.02% |
| Michael Lynton | Independent Chairperson | 0.02% |
| Nancy Thornberry | Independent Director | 0.02% |
| Jeffrey Chodakewitz | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Karen Akinsanya | President of Research & Development Therapeutics | Derivative Exercise and Sale | -31,599 | $4.34–30.00 |
| 2026-07-15 | Richie Jain | Senior Vice President of Strategic Finance & Business Development | Automatic Disposition | -875 | $15.60 |
| 2026-06-30 | Mannix Aklian | -- | Intent to Sell (Form 144) | -1,136 | $16.68 |
| 2026-06-25 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Acquisition | +679,373 | -- |
| 2026-06-25 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Disposition | -679,373 | -- |
| 2026-06-21 | Michael Lynton | Independent Chairperson | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Michael Lynton | Independent Chairperson | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Gary Ginsberg | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Gary Ginsberg | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Gary Sender | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Gary Sender | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Arun Oberoi | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Arun Oberoi | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Rosana Kapeller-Libermann | Independent Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Rosana Kapeller-Libermann | Independent Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Bridget van Kralingen | Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Bridget van Kralingen | Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Acquisition | +8,141 | -- |
| 2026-06-21 | Richard Friesner | Co-Founder, Scientific Advisory Chairman and Director | Other Derivative Acquisition | +13,313 | $15.23 |
| 2026-06-21 | Nancy Thornberry | Independent Director | Other Acquisition | +8,141 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:53:52 · For reference only, not investment advice and not tailored to your situation.